(GHRS) GH Research - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.466m USD | Total Return: 96.3% in 12m
Avg Turnover: 4.24M
Warnings
High Debt while negative Cash Flow
Interest Coverage Ratio -159.1 is critical
Altman Z'' -11.98 < 1.0 - financial distress zone
Fakeout Choppy
Tailwinds
Leader
GH Research PLC (GHRS) is a Dublin-based clinical-stage biopharmaceutical firm specializing in the development of mebufotenin-based therapies for psychiatric disorders. The company’s primary focus is GH001, an inhalable candidate currently in Phase 2b trials for treatment-resistant depression (TRD) and Phase 2a trials for bipolar II and postpartum depression. Additionally, the firm is evaluating GH002, an intravenous formulation, in Phase 1 clinical pharmacology studies.
The biotechnology sector often utilizes psychedelic compounds like mebufotenin (5-MeO-DMT) to target neurotransmitter pathways that traditional antidepressants may not adequately address. Clinical-stage companies in this space typically operate without recurring revenue, relying on venture funding or public offerings to finance the multi-year regulatory approval process required by the FDA.
Investors can further evaluate the companys clinical milestones and pipeline progress by reviewing the data available on ValueRay. GH Research continues to advance its proprietary aerosol delivery systems to optimize the rapid-onset potential of its lead compounds.
- GH001 Phase 2b clinical trial results for treatment-resistant depression determine valuation
- FDA regulatory clearance for US Investigational New Drug application impacts timeline
- Proprietary aerosol delivery technology performance influences competitive advantage in psychedelics
- Cash runway and financing needs for late-stage clinical development costs
- Market penetration potential for mebufotenin against established depression treatment alternatives
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -4.01 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 > 3% & CFO -46.3m > Net Income -56.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 23.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.0m) vs 12m ago 6.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -159.1 > 6 (EBITDA TTM -58.4m / Interest Expense TTM 369k) |
| A: 0.95 (Total Current Assets 272.2m - Total Current Liabilities 11.8m) / Total Assets 275.3m |
| B: -0.63 (Retained Earnings -173.2m / Total Assets 275.3m) |
| C: -0.20 (EBIT TTM -58.7m / Avg Total Assets 297.9m) |
| D: -14.11 (Book Value of Equity -167.8m / Total Liabilities 11.9m) |
| Altman-Z'' = -11.98 = D |
As of May 24, 2026, the stock is trading at USD 21.77 with a total of 294,563 shares traded.
Over the past week, the price has changed by +3.41%,
over one month by +16.73%,
over three months by +43.45% and
over the past year by +96.27%.
GH Research has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy GHRS.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 41.3 | 89.7% |
Revenue TTM = 0.0 USD
EBIT TTM = -58.7m USD
EBITDA TTM = -58.4m USD
Long Term Debt = 75.0k USD (estimated: total debt 432k - short term 357k)
Short Term Debt = 357k USD (from shortTermDebt, last quarter)
Debt = 944k USD (from shortLongTermDebtTotal, last quarter) + Leases 512k
Net Debt = -266.4m USD (calculated: Debt 944k - CCE 267.3m)
Enterprise Value = 1.20b USD (1.47b + Debt 944k - CCE 267.3m)
Interest Coverage Ratio = -159.1 (Ebit TTM -58.7m / Interest Expense TTM 369k)
EV/FCF = -25.80x (Enterprise Value 1.20b / FCF TTM -46.5m)
FCF Yield = -3.88% (FCF TTM -46.5m / Enterprise Value 1.20b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 350k) / Revenue TTM)
Tobins Q-Ratio = 4.36 (Enterprise Value 1.20b / Total Assets 275.3m)
Interest Expense / Debt = 39.09% (Interest Expense 369k / Debt 944k)
Taxrate = 21.0% (US default 21%)
NOPAT = -46.4m (EBIT -58.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 23.04 (Total Current Assets 272.2m / Total Current Liabilities 11.8m)
Debt / Equity = 0.00 (Debt 944k / totalStockholderEquity, last quarter 263.4m)
Debt / EBITDA = 4.56 (negative EBITDA) (Net Debt -266.4m / EBITDA -58.4m)
Debt / FCF = 5.73 (negative FCF - burning cash) (Net Debt -266.4m / FCF TTM -46.5m)
Total Stockholder Equity = 284.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.94% (Net Income -56.4m / Total Assets 275.3m)
RoE = -12.33% (Net Income TTM -56.4m / Total Stockholder Equity 457.6m)
RoCE = -12.83% (EBIT -58.7m / Capital Employed (Equity 457.6m + L.T.Debt 75.0k))
RoIC = -18.42% (negative operating profit) (NOPAT -46.4m / Invested Capital 251.9m)
WACC = 10.95% (E(1.47b)/V(1.47b) * Re(10.94%) + D(944k)/V(1.47b) * Rd(39.09%) * (1-Tc(0.21)))
Discount Rate = 10.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.89 | Cagr: 8.13%
[DCF] Fair Price = unknown (Cash Flow -46.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.74 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.32 | Chg30d=-11.48% | Revisions=-20% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-8.82% | Revisions=-20% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.43 | Chg30d=-7.98% | Revisions=+0% | GrowthEPS=-81.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.99 | Chg30d=-8.27% | Revisions=-40% | GrowthEPS=-39.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -40%